Important Preventive Accumulation about LEXIVA.

HIV medicines do not cure HIV infection/AIDS or prevent death HIV to others.


LEXIVA is contraindicated in patients with previously demonstrated clinically significant sensibility to any of the components of this good or to amprenavir. Hyperglycemia, new attack or exacerbations of diabetes mellitus, and spontaneous bleeding in hemophiliacs have been reported with protease inhibitors.


Redistribution/accumulation of body fat including central obesity, dorsocervical fat photo (buffalo hump), peripheral cachexia, cranial nerve debility, tit blowup and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The causal state, carrying out and long-term consequences of these events are currently terra incognita.


LEXIVA should be used with attentiveness in patients with a known sulfonamide allergy.


Severe or life-threatening skin reactions were reported in less than 1 percent of 700 patients treated with LEXIVA in clinical studies, including one case of Stevens-Johnson composite.


Skin rashes (all grades, without item to causality) occurred in approximately 19 percent of patients treated with LEXIVA in the pivotal efficacy studies. This led to the discontinuation of LEXIVA in less than 1 percent of patients.